Partial inhibition of the ubiquitin–proteasome system ameliorates cardiac dysfunction following ischemia–reperfusion in the presence of high glucose

Cardiovascular Diabetology

M Faadiel Essop¹  Rudo F Mapanga¹  Buin Adams¹ 

[1] Cardio-Metabolic Research Group (CMRG), Department of Physiological Sciences, Stellenbosch University, Room 2005, Mike De Vries Building, Merriman Avenue, Stellenbosch 7600, South Africa

关键词: Autophagy;    Oxidative stress;    Inflammation;    Hyperglycemia;    Cardiac dysfunction;    Ischemia–reperfusion;    Ubiquitin–proteasome system;   

Others  :  1221202
DOI  :  10.1186/s12933-015-0258-4

 received in 2015-04-28, accepted in 2015-07-17,  发布年份 2015

【 摘 要 】

Background

Acute hyperglycemia co-presenting with myocardial infarction (in diabetic and non-diabetic individuals) is often associated with a poor prognosis. Although acute hyperglycemia induces oxidative stress that can lead to dysregulation of the ubiquitin–proteasome system (UPS), it is unclear whether increased/decreased UPS is detrimental with ischemia–reperfusion under such conditions. As our earlier data implicated the UPS in cardiac damage, we hypothesized that its inhibition results in cardioprotection with ischemia–reperfusion performed under conditions that simulate acute hyperglycemia.

Methods

Ex vivo rat heart perfusions were performed with Krebs–Henseleit buffer containing 33 mM glucose vs. controls (11 mM glucose) for 60 min stabilization, followed by 20 min global ischemia and 60 min reperfusion ± 5 µM lactacystin and 10 µM MG-132, respectively. The UPS inhibitors were added during the first 20 min of the reperfusion phase and various cardiac functional parameters evaluated. In parallel experiments, infarct sizes were assessed following 20 min regional ischemia and 120 min reperfusion ± each of the respective UPS inhibitors (added during reperfusion). Heart tissues were collected and analyzed for markers of oxidative stress, UPS activation, inflammation and autophagy.

Results

The proteasome inhibitor doses and treatment duration here employed resulted in partial UPS inhibition during the reperfusion phase. Both lactacystin and MG-132 administration resulted in cardioprotection in our experimental system, with MG-132 showing a greater effect. The proteasome inhibitors also enhanced cardiac superoxide dismutase protein levels (SOD1, SOD2), attenuated pro-inflammatory effects and caused an upregulation of autophagic markers.

Conclusions

This study established that partial proteasome inhibition elicits cardioprotection in hearts exposed to ischemia–reperfusion with acute simulated hyperglycemia. These data reveal that protease inhibition triggered three major protective effects, i.e. (a) enhancing myocardial anti-oxidant defenses, (b) attenuating inflammation, and (c) increasing the autophagic response. Thus the UPS emerges as a unique therapeutic target for the treatment of ischemic heart disease under such conditions.

【 授权许可】

   
2015 Adams et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

Fig.5.

Fig.6.

Fig.7.

Fig.8.

Fig.9.

Fig.10.

【 参考文献 】

• [1]Soedamah-Muthu S, Fuller J, Mulnier HE, Raleigh VS, Lawrenson R, Colhoun HM. High risk of cardiovascular disease in a cohort study using the General Practice Research Database. Diabetes Care. 2006; 29:798-804.
• [2]Gardner A. The benefits of tight glycemic control in critical illness: sweeter than assumed? Indian J Crit Care Med. 2014; 18(12):807.
• [3]Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014; 5(4):444-470.
• [4]Marcovecchio ML, Lucantoni M, Chiarelli F. Role of chronic and cute hyperglycemia in the development of diabetes complications. Diabetes Technol Ther. 2011; 13:389-394.
• [5]Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with T2DM (UKPDS 33). Lancet. 1998; 352:837-845.
• [6]The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-986.
• [7]Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34:29-34.
• [8]Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000; 355:773-778.
• [9]Marfella R, Di Filippo C, Portoghese M, Ferraraccio F, Rizzo MR, Siniscalchi M et al.. Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol. 2009; 53(16):1425-1436.
• [10]Sleiman I, Morandi A, Sabatini T, Ranhoff A, Ricci A, Rozzini R et al.. Hyperglycemia as a predictor of in-hospital mortality in elderly patients without diabetes mellitus admitted to a sub-intensive care unit. J Am Geriatr Soc. 2008; 56(6):1106-1110.
• [11]Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L et al.. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002; 359:2140-2144.
• [12]Sawin G, Shaughnessy AF. Glucose control in hospitalized patients. Am Fam Physician. 2010; 81(9):1121-1124.
• [13]Powell SR. The ubiquitin–proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol. 2006; 291:H1-H19.
• [14]Kriegenburg F, Ellgaard L, Hartmann-Petersen R. Molecular chaperones in targeting misfolded proteins for ubiquitin-dependent degradation. FEBS J. 2012; 279(4):532-542.
• [15]Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y et al.. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB. Am J Physiol Heart Circ Physiol. 2013; 304(4):H567-H578.
• [16]Marfella R, Di C, Portoghese M, Siniscalchi M, Martis S, Ferraraccio F et al.. The ubiquitin–proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium : the role of glycemic control. Cardiovasc Pathol. 2009; 18(6):332-345.
• [17]Huang S, Patterson E, Yu X, Garrett MW, De Aos I, Kem DC. Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2008; 294(3):H1298-H1303.
• [18]Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B et al.. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem. 2001; 276(32):30057-30063.
• [19]Zolk O, Schenke C, Sarikas A. The ubiquitin–proteasome system: focus on the heart. Cardiovasc Res. 2006; 70(3):410-421.
• [20]Calise J, Powell SR. The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol. 2013; 304(3):H337-H349.
• [21]Mapanga R, Rajamani U, Dlamini N, Zungu-Edmondson M, Kelly-Laubscher R, Shafiullah M et al.. Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. PLoS One. 2012; 7(10):e47322.
• [22]Mapanga RF, Joseph D, Symington B, Garson K-L, Kimar C, Kelly-Laubscher R et al.. Detrimental effects of acute hyperglycaemia on the rat heart. Acta Physiol (Oxf). 2014; 210:546-564.
• [23]Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev. 2012; 32(6):1292-1327.
• [24]Fenteany G, Standaert R, Lane W, Choi S, Corey E, Schreiber S. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995; 268:726-731.
• [25]Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev. 2007; 107(3):687-717.
• [26]Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL et al.. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. 1997; 272(20):13437-13445.
• [27]Divald A, Powell SR. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med. 2006; 40:156-164.
• [28]Powell S, Wang P, Katzeff H, Shringarpure R, Teoh C, Khaliulin I et al.. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal. 2005; 7:538-546.
• [29]Rajamani U, Joseph D, Roux S, Essop MF. The hexosamine biosynthetic pathway can mediate myocardial apoptosis in a rat model of diet-induced insulin resistance. Acta Physiol (Oxf). 2011; 202(2):151-157.
• [30]Rajamani U, Essop MF. Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am J Physiol Cell Physiol. 2010; 299(1):C139-C147.
• [31]Yu X, Kem DC. Proteasome inhibition during myocardial infarction. Cardiovasc Res. 2010; 85:312-320.
• [32]Campbell B, Adams J, Shin Y, Lefer A. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol. 1999; 31:467-476.
• [33]Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J et al.. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol. 2003; 284(3):H919-H926.
• [34]Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia–reperfusion injury. Ann Thorac Surg. 2007; 84(1):120-125.
• [35]Wang X, Robbins J. Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol. 2014; 71:16-24.
• [36]Tian Z, Zheng H, Li J, Li Y, Su H, Wang X. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia–reperfusion injury in Mice. Circ Res. 2012; 111(5):532-542.
• [37]Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001; 8(8):739-758.
• [38]Ma Y, Chen B, Liu D, Yang Y, Xiong Z, Zeng J et al.. MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κβ/TGFβ1 pathway. Biochem Pharmacol. 2011; 81(10):1228-1236.
• [39]Stangl K, Günther C, Frank T, Lorenz M, Meiners S, Röpke T et al.. Inhibition of the ubiquitin–proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem Biophys Res Commun. 2002; 291:542-549.
• [40]Kassiotis C, Rajabi M, Taegtmeyer H. Metabolic reserve of the heart: the forgotten link between contraction and coronary flow. Prog Cardiovasc Dis. 2008; 51(1):74-88.
• [41]Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation. 1998; 98(14):1355-1357.
• [42]Murriel CL, Churchill E, Inagaki K, Szweda LI, Mochly-Rosen D. Protein kinase C delta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J Biol Chem. 2004; 279(46):47985-47991.
• [43]Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54:1615-1625.
• [44]Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B et al.. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia. 1997; 40:647-653.
• [45]Rösen P, Du X, Tschöpe D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention with alpha tocopherol? Mol Cell Biochem. 1998; 188:103-111.
• [46]Holtzclaw WD, Dinkova-Kostova AT, Talalay P. Protection against electrophile and oxidative stress by induction of phase 2 genes: the quest for the elusive sensor that responds to inducers. Adv Enzyme Regul. 2004; 44:335-367.
• [47]Kobayashi A, Ohta T, Yamamoto M. Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol. 2000; 2004(378):273-286.
• [48]McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003; 278(24):21592-21600.
• [49]Kobayashi A, Kang M, Okawa H, Zenke Y, Chiba T, Igarashi K et al.. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24(16):7130-7139.
• [50]Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem. 2005; 280(34):30091-30099.
• [51]Willis MS, Townley-Tilson WHD, Kang EY, Homeister JW, Patterson C. Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res. 2010; 106(3):463-478.
• [52]Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010; 584(7):1393-1398.
• [53]Zheng Q, Su H, Tian Z, Wang X. Proteasome malfunction activates macroautophagy in the heart. Am J Cardiovasc Dis. 2011; 1(3):214-226.
• [54]Wang B, Yang Q, Sun YY, Xing YF, Bin WY, Lu XT et al.. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med. 2014; 18(8):1599-1611.